Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
|Articles|April 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 4
- Volume 16
- Issue 4
GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
Advertisement
PHILADELPHIA, PennsylvaniaGlaxoSmithKline has submitted to the FDA a Biologics License Application (BLA) for Cervarix (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer candidate vaccine. The vaccine is formulated with a proprietary adjuvant system called AS04 containing aluminum hydroxide and monophosphoryl lipid A. The submission includes data from clinical trials in almost 30,000 females age 10 to 55 reflecting an ethnically diverse population, the company said.
Articles in this issue
over 19 years ago
Curcumin Evaluated for the Treatment of Pancreatic Cancerover 19 years ago
Tykerb Approved for Metastatic HER2+ Breast Cancerover 19 years ago
Drug for BPH May Also Reduce the Risk of Prostate Cancerover 19 years ago
Phase III Trial of Prostvac-VF Is Launchedover 19 years ago
Electronic System Reminds Patients to Schedule Examsover 19 years ago
Phase II Trial of Panzem for Renal Cell Carcinoma Initiatedover 19 years ago
Chemotherapy May Enrich Tumorigenic Cells in Breast Caover 19 years ago
Watchful Waiting Management for Prostate Ca a Hard SellAdvertisement
Related to this article
Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.
Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy.
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
A flood-damaged Pfizer joint-venture plant in India that makes injectable chemotherapy may not resume supply until mid-to-late 2028.
Preoperative botensilimab plus balstilimab produced a pathologic major response in 36% of patients with pMMR and 100% of those with dMMR resectable colon cancer.
Sunnie Kim, MD, explains how she uses baseline and postsurgical ctDNA to guide de-escalation conversations for patients struggling after surgery.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the Gaps in Precision Oncology for Breast Cancer
2
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5